Primary cutaneous marginal zone lymphoma

From WikiMD's WELLNESSPEDIA


Primary cutaneous marginal zone lymphoma
Synonyms PCMZL
Pronounce N/A
Specialty N/A
Symptoms Skin lesions, Nodules, Plaques
Complications Secondary infections, Ulceration
Onset Middle age
Duration Chronic
Types N/A
Causes Unknown, possible Borrelia burgdorferi association
Risks Immunosuppression, Autoimmune disorders
Diagnosis Skin biopsy, Histopathology
Differential diagnosis Cutaneous B-cell lymphoma, Cutaneous T-cell lymphoma, Pseudolymphoma
Prevention N/A
Treatment Radiation therapy, Surgical excision, Intralesional corticosteroids
Medication N/A
Prognosis Generally Indolent with good prognosis
Frequency Rare
Deaths N/A


Primary cutaneous marginal zone lymphoma (PCMZL) is a type of extranodal marginal zone B-cell lymphoma that primarily affects the skin. It is classified as a low-grade B-cell lymphoma and is part of the group of mucosa-associated lymphoid tissue (MALT) lymphomas. PCMZL is characterized by the proliferation of small B-cells, including marginal zone cells, monocytoid cells, and small lymphocytes, often with reactive germinal centers.

Clinical Presentation[edit]

PCMZL typically presents as solitary or multiple skin lesions, which may appear as red or violaceous papules, nodules, or plaques. These lesions are most commonly found on the arms, trunk, or back, but can occur anywhere on the body. The condition is generally indolent, meaning it progresses slowly and is often asymptomatic.

Pathophysiology[edit]

The exact cause of PCMZL is not well understood, but it is thought to be associated with chronic antigenic stimulation. This can be due to infections, such as Borrelia burgdorferi (the bacterium responsible for Lyme disease), or autoimmune conditions. The lymphoma cells in PCMZL are typically CD20 positive and may express other B-cell markers such as CD79a and Bcl-2, but they are usually negative for CD5, CD10, and cyclin D1.

Diagnosis[edit]

Diagnosis of PCMZL is based on clinical examination, histopathological analysis, and immunohistochemical staining of a skin biopsy. The biopsy typically shows a dense infiltrate of small B-cells in the dermis, often with reactive germinal centers. Molecular studies may reveal clonal immunoglobulin gene rearrangements, supporting the diagnosis of a B-cell lymphoma.

Treatment[edit]

Treatment options for PCMZL depend on the extent and location of the disease. Localized lesions may be treated with surgical excision or radiation therapy. In cases with multiple lesions or more extensive disease, systemic therapies such as rituximab (an anti-CD20 monoclonal antibody) or low-dose chemotherapy may be considered. The prognosis for PCMZL is generally favorable, with a high rate of long-term survival.

Prognosis[edit]

PCMZL is considered an indolent lymphoma with an excellent prognosis. Most patients experience long-term survival, and the disease rarely progresses to a more aggressive form. However, recurrences are common, and ongoing monitoring is recommended.

Related Pages[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Primary_cutaneous_marginal_zone_lymphoma&oldid=6542564"